Karyopharm to Present at Oppenheimer 25th Annual Healthcare Conference
December 04, 2014 16:01 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that Justin A. Renz, Executive Vice President and...
Karyopharm to Present Clinical Data Update for Selinexor (KPT-330) in Oncology
December 01, 2014 16:01 ET
|
Karyopharm Therapeutics
- Presentation to Include Discussion of Selinexor as Single-Agent and in Combination to Treat Hematological Malignancies -
- Webcast Event Scheduled for Monday, December 8, 2014 at 8:30 p.m. PST...
Karyopharm Announces Additional Orphan Designations Granted for Selinexor (KPT-330) by European Commission
December 01, 2014 08:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that its lead drug candidate, Selinexor (KPT-330),...
Karyopharm Presents Data on Oncology Pipeline at EORTC-NCI-AACR Annual Meeting
November 24, 2014 08:00 ET
|
Karyopharm Therapeutics
- Selinexor Synergy with DNA Damage Inducing Treatments Provides Potential for Improved Clinical Outcomes -
- XPO1 Occupancy Assay Developed to Evaluate Selinexor Binding to its Target and...
Karyopharm Reports Third Quarter 2014 Financial Results and Highlights Recent Progress
November 10, 2014 07:05 ET
|
Karyopharm Therapeutics
- Reported Positive Phase 1 Clinical Data Demonstrating Early Signs of Activity for Selinexor in Several Solid Tumor Settings -
- Initiated SIRTT, an Additional Registration-Directed Trial for...
Karyopharm Initiates Registration-Directed Clinical Study of Selinexor (KPT-330) in Patients With Richter's Transformation
November 10, 2014 07:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the initiation of its Phase 2 study of Selinexor...
Karyopharm Announces Data Presentations at American Society of Hematology Annual Meeting
November 06, 2014 09:01 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that clinical and pre-clinical data for its lead...
Karyopharm to Present at Credit Suisse 2014 Healthcare Conference
November 05, 2014 08:30 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today that Michael G. Kauffman, MD, PhD, Chief Executive Officer of...
Karyopharm Appoints J. Scott Garland to Its Board of Directors
November 04, 2014 07:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of J. Scott Garland, Senior Vice...
Karyopharm to Report Third Quarter 2014 Financial Results on November 10, 2014
October 30, 2014 08:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company today announced it will report third quarter 2014 financial results...